

## Publications LBI members 2019-2025



*Original publications Programme Line 1 Epidemiology*

2025

### **Fractional exhaled nitric oxide in a respiratory healthy general population through the lifespan.**

Bal C, Schiffers C, Breyer MK, Hartl S, Agusti A, Karimi A, Pohl W, Idzko M, Breyer-Kohansal R.  
Pulmonology. 2025 Dec 31;31(1):2442662. doi: 10.1080/25310429.2024.2442662. Epub 2025 Jan 6. IF: 11.4

2024

### **Oscillometry reference values for children and adolescents.**

Valach C, Wouters EFM, Ofenheimer A, Pompilio PP, Gobbi A, Breyer MK, Hartl S, Veneroni C, Mraz T, Schiffers C, Burghuber OC, Karimi A, Gross C, Irvin C, Breyer-Kohansal R.  
ERJ Open Res. 2024 Dec 16;10(6):00278-2024. doi: 10.1183/23120541.00278-2024. IF: 16.6

### **Type-2 Inflammation in Health and Disease: Prevalence, Risk Factors and Multimorbidity**

Lim, C.J.M.; Gross, C.; Breyer, M.-K.; Breyer-Kohansal, R.; Wouters, E.F.M.; Hartl, S.  
J Clin Med. 2024 Nov 6;13(22):6662. doi: 10.3390/jcm13226662. IF: 3.6

### **Reference equations for pulse wave velocity, augmentation index, amplitude of forward and backward wave in a European general adult population.**

Azizzadeh M, Karimi A, Breyer-Kohansal R, Hartl S, Breyer MK, Gross C, Boutouyrie P, Bruno RM, Hametner B, Wassertheurer S, Burghuber OC, Weber T.  
Sci Rep. 2024 Oct 5;14(1):23151. doi: 10.1038/s41598-024-74162-5. IF.: 3.8

### **Prevalence and etiotypes of persistent airflow obstruction in the general population ACROSS THE LIFETIME**

Grasl MT, Agusti A, Azizzadeh M, Karimi A, Hartl S, Breyer MK, Breyer-Kohansal R.  
Respir Med. 2024 Nov;233:107779. doi: 10.1016/j.rmed.2024.107779. Epub 2024 Aug 22. IF: 3.7

### **Associations of long-term exposure to air pollution and noise with body composition in children and adults: Results from the LEAD general population study.**

Altug H, Ogurtsova K, Breyer-Kohansal R, Schiffers C, Ofenheimer A, Tzivian L, Hartl S, Hoffmann B, Lucht S, Breyer MK.  
Environ Int. 2024 Jul;189:108799. doi: 10.1016/j.envint.2024.108799. Epub 2024 Jun 5. ERS. IF: 11.8

### **Reference equations for within-breath respiratory oscillometry in White adults.**

Veneroni C, Gobbi A, Pompilio PP, Dellacà R, Fasola S, La Grutta S, Leyva A, Porszasz J, Stornelli SR, Fuso L, Valach C, Breyer-Kohansal R, Breyer MK, Hartl S, Contu C, Inchingolo R, Hodgdon K, Kaminsky DA.  
Respiration. 2024;103(9):521-534. doi: 10.1159/000539532. Epub 2024 Jun 7. IF: 3.7

### **Association of Preserved Ratio Impaired Spirometry (PRISm) with Arterial Stiffness.**

Kaufmann CC, Breyer MK, Hartl S, Gross C, Schiffers C, Wouters EFM, Breyer-Kohansal R, Weber T, Huber K, Agusti A, Burghuber OC.  
Ann Am Thorac Soc. 2024 Sep;21(9):1289-1298. doi: 10.1513/AnnalsATS.202310-859OC. IF: 5.102

### **Updated reference values for static lung volumes from a healthy population in Austria.**

Mraz T, Asgari S, Karimi A, Breyer MK, Hartl S, Sunanta O, Ofenheimer A, Burghuber OC, Zacharasiewicz A, Lamprecht B, Schiffers C, Wouters EFM, Breyer-Kohansal R.  
Respir Res. 2024 Apr 3;25(1):155. doi: 10.1186/s12931-024-02782-6. IF: 5.8

### **The effect of body compartments on lung function in childhood and adolescence**

Ofenheimer A, Breyer MK, Wouters EFM, Schiffers C, Hartl S, Burghuber OC, Krach F, Maninno DM, Franssen FME, Mraz T, Puchhammer P, Breyer-Kohansal R.  
Clin Nutr. 2024 Feb;43(2):476-481. doi: 10.1016/j.clnu.2023.12.010. Epub 2023 Dec 27. IF: 6.77

### **Diagnostic Potential of Oscillometry: A Population-based Approach**

Veneroni C, Valach C, Wouters EFM, Gobbi A, Dellacà RL, Breyer MK, Hartl S, Sunanta O, Irvin CG, Schiffers C, Pompilio PP, Breyer-Kohansal R.  
Am J Respir Crit Care Med. 2024 Feb 15;209(4):444-453. doi: 10.1164/rccm.202306-0975OC. IF: 2.5

## **2023**

### **Restrictive Spirometry or PRISm: Does it Matter?**

Schiffers C, Mraz T, Breyer MK, Hartl S, Breyer-Kohansal R, Wouters EFM.  
Am J Respir Crit Care Med. 2023 Oct 15;208(8):905-907. doi: 10.1164/rccm.202304-0765LE. IF: 24.7

### **Supranormal lung function: Prevalence, associated factors and clinical manifestations across the lifespan.**

Schiffers C, Faner R, Ofenheimer A, Sunanta O, Puchhammer P, Mraz T, Breyer MK, Burghuber OC, Hartl S, Agustí A, Breyer-Kohansal R.  
Respirology. 2023 Oct;28(10):942-953. IF: 6.9

### **Prevalence of restrictive lung function in children and adults in the general population.**

Schiffers C, Ofenheimer A, Breyer MK, Mraz T, Lamprecht B, Burghuber OC, Hartl S, Wouters EFM, Breyer-Kohansal R.  
Respir Med. 2023 Apr-May;210:107156. doi: 10.1111/resp.14553. Epub 2023 Jul 11. IF: 4.582

### **Asthma Prevalence and Phenotyping in the General Population: The LEAD (Lung, hEart, sociAl, boDy) Study.**

Schiffers C, Wouters EFM, Breyer-Kohansal R, Buhl R, Pohl W, Irvin CG, Breyer MK, Hartl S.  
J Asthma Allergy. 2023 Apr 8;16:367-382. doi: 10.2147/JAA.S402326. eCollection 2023. IF: 2.515

## **2022**

### **Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology.**

Perkmann T, Koller T, Perkmann-Nagele N, Ozsvar-Kozma M, Eyre D, Matthews P, Bown A, Stoesser N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghar D, Quehenberger P, Marculescu R, Mucher P, Radakovics A, Klausberger M, Duerkop M, Holzer B, Hartmann B, Strassl R, Leitner G, Grebien F, Gerner W, Grabherr R, Wagner OF, Binder CJ, Haslacher H.  
J Clin Pathol. 2023 Nov;76(11):770-777. doi: 10.1136/jcp-2022-208171. Epub 2022 Aug 30.. IF:3.61

### **Aero-allergen sensitization in the general population: Longitudinal analyses of the LEAD (Lung Heart Social Body) Study.**

Kölli F, Breyer MK, Hartl S, Burghuber OC, Wouters EFM, Sigsgaard T, Pohl W, Kohlböck G, Breyer-Kohansal R.  
J Asthma Allergy. 2022 Apr 11;15:461-473. doi: 10.2147/JAA.S349614. eCollection 2022. IF: 4.258.

### **Distribution of chronic cough phenotypes in the general population: A cross-sectional analysis of the LEAD cohort in Austria.**

Abozid H, Baxter CA, Hartl S, Braun E, Salomonsson S, Breyer-Kohansal R, Breyer MK, Wouters EFM, Agustí A, Burghuber OC.  
Respir Med. 2022 Feb;192:106726. doi: 10.1016/j.rmed.2021.106726. Epub 2021 Dec 30. IF: 3.415.

**Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies.**

Allinson JP, Afzal S, Çolak Y, Jarvis D, Backman H, van den Berge M, Boezen HM, Breyer MK, Breyer-Kohansal R, Brusselle G, Burghuber OC, Faner R, Hartl S, Lahousse L, Langhammer A, Lundbäck B, Nwaru BI, Rönmark E, Vikjord SAA, Vonk JM, Wijnant SRA, Lange P, Nordestgaard BG, Olvera N, Agusti A, Donaldson GC, Wedzicha JA, Vestbo J, Vanfleteren LEGW.

CADSET Clinical Research Collaboration. *Lancet Respir Med.* 2022 Jan;10(1):83-94.

doi: 10.1016/S2213-2600(21)00313-1. Epub 2021 Oct 4. IF: 102.731

**2021**

**Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study.**

Wang G, Hallberg J, Charalampopoulos D, Sanahuja MC, Breyer-Kohansal R, Langhammer A, Granell R, Vonk JM, Mian A, Olvera N, Laustsen LM, Rönmark E, Abellan A, Agusti A, Arshad SH, Bergström A, Boezen HM, Breyer MK, Burghuber O, Bolund AC, Custovic A, Devereux G, Donaldson GC, Duijts L, Esplugues A, Faner R, Ballester F, Garcia-Aymerich J, Gehring U, Haider S, Hartl S, Backman H, Holloway JW, Koppelman GH, Lertxundi A, Holmen TL, Lowe L, Mensink-Bout SM, Murray CS, Roberts G, Hedman L, Schlünssen V, Sigsgaard T, Simpson A, Sunyer J, Torrent M, Turner S, Van den Berge M, Vermeulen RCH, Vikjord SAA, Wedzicha JA, Maitland van der Zee AH, Melén E.

*ERJ Open Res.* 2021 Dec 6;7(4):00457-2021. doi: 10.1183/23120541.00457-2021.

eCollection 2021 Oct. IF: 4.2

**Using Body Composition Groups to Identify Children and Adolescents at Risk of Dyslipidemia.**

Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Franssen FME, Wouters EFM, Breyer MK.

*Children (Basel).* 2021 Nov 13;8(11):1047. doi: 10.3390/children8111047. IF: 2.863

**A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests.**

Klausberger M, Duerkop M, Haslacher H, Wozniak-Knopp G, Cserjan-Puschmann M, Perkmann T, Lingg N, Aguilar PP, Laurent E, De Vos J, Hofner M, Holzer B, Stadler M, Manhart G, Vierlinger K, Egger M, Milchram L, Gludovacz E, Marx N, Köppl C, Tauer C, Beck J, Maresch D, Grünwald-Gruber C, Strobl F, Satzer P, Stadlmayr G, Vavra U, Huber J, Wahrmann M, Eskandary F, Breyer MK, Sieghart D, Quehenberger P, Leitner G, Strassl R, Egger AE, Irsara C, Griesmacher A, Hoermann G, Weiss G, Bellmann-Weiler R, Loeffler-Ragg J, Borth N, Strasser R, Jungbauer A, Hahn R, Mairhofer J, Hartmann B, Binder NB, Striedner G, Mach L, Weinhäusel A, Dieplinger B, Grebien F, Gerner W, Binder CJ, Grabherr R.

*EBioMedicine.* 2021 May; 67:103348. doi: 10.1016/j.ebiom.2021.103348. Epub 2021 Apr 25. IF: 8.143

**Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.**

Breyer MK, Breyer-Kohansal R, Hartl S, Kundi M, Weseslindtner L, Stiasny K, Puchhammer-Stöckl E, Schrott A, Födinger M, Binder M, Fiedler M, Wouters EFM, Burghuber OC.

*Sci Rep.* 2021 May 12;11, (1):10158 (2021). doi: 10.1038/s41598-021-89711-5. IF: 4.996

**Reference charts for body composition parameters by dual-energy X-ray absorptiometry in European children and adolescents aged 6 to 18 years-Results from the Austrian LEAD (Lung, hEart, sociAl, boDy) cohort.**

Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Schrott A, Franssen FME, Wouters EFM, Breyer MK.

*Pediatr Obes.* 2021 Jan;16(1):e12695. doi: 10.1111/ijpo.12695. Epub 2020 Jul 2. IF: 3.429

2020

**Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity.**

Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Strassl R, Wagner OF, Binder CJ, Haslacher H. Clin Chem. 2020 Nov 1;66(11):1405-1413. doi: 10.1093/clinchem/hvaa198. IF: 7.292

**Reference values of body composition parameters and visceral adipose tissue (VAT) by DXA in adults aged 18-81 years-results from the LEAD cohort.**

Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Schrott A, Wouters EFM, Franssen FME, Breyer MK. Eur J Clin Nutr 2020 Aug;74(8):1181-1191. doi: 10.1038/s41430-020-0596-5. Epub 2020 Mar 2. IF: 3.291

**Factors Associated with Low Lung Function in Different Age Bins in the General Population.** Breyer-Kohansal R, Faner R, Breyer MK, Ofenheimer A, Schrott A, Studnicka M, Wouters EFM, Burghuber OC, Hartl S, Agusti A.

Am J Respir Crit Care Med 2020 Jul 15;202(2):292-296. doi: 10.1164/rccm.202001-0172LE. IF: 21.405

**Blood eosinophil count in the general population: typical values and potential confounders.** Hartl S, Breyer MK, Burghuber OC, Ofenheimer A, Schrott A, Urban MH, Agusti A, Studnicka M, Wouters EFM, Breyer-Kohansal R.

Eur Respir J. 2020 May 14;55(5):1901874. doi: 10.1183/13993003.01874-2019. Print 2020 May. IF: 12.339

**Marked differences in prediabetes- and diabetes-associated comorbidities between men and women- Epidemiological results from a general population-based cohort aged 6-80 years -The LEAD (Lung, hEart, sociAl, boDy) study.**

Breyer MK, Ofenheimer A, Altziebler J, Hartl S, Burghuber OC, Studnicka M, Purin D, Heinzle C, Drexel H, Franssen FME, Wouters EFM, Harreiter J, Kautzky-Willer A, Breyer-Kohansal R. Eur J Clin Invest. 2020 Mar;50(3):e13207. doi: 10.1111/eci.13207. Epub 2020 Feb 12. IF: 3.481

2019

**The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study.**

Breyer-Kohansal R, Hartl S, Burghuber OC, Urban M, Schrott A, Agusti A, Sigsgaard T, Vogelmeier C, Wouters EFM, Studnicka M, Breyer MK. J Epidemiol. 2019 Aug 5;29(8):315-324. doi: 10.2188/jea.JE20180039. Epub 2018 Oct 20. IF: 7.707

*Reviews and editorials*

2024

**Oscillometry in chronic cough: data from a general population cohort.**

Abozid H, Wouters EFM, Breyer MK. Respiration. 2024 Jun 3. doi: 10.1159/000539327. Epub 2024 Jun 3. IF: 3.7

### **Lung-function trajectories: relevance and implementation in clinical practice**

Melén E, Faner R, Allinson JP, Bui D, Bush A, Custovic A, Garcia-Aymerich J, Guerra S, Breyer-Kohansal R, Hallberg J, Lahousse L, Martinez FD, Kebede Merid S, Powell P, Pinnock H, Stanojevic S, Vanfleteren LEGW, Wang G, Dharmage SC, Wedzicha J, Agusti A; CADSET Investigators  
Lancet. 2024 Apr 13;403(10435):1494-1503. doi: 10.1016/S0140-6736(24)00016-3. Epub 2024 Mar 12. IF: 168.9

## **2023**

### **Prevalence of dyspnea in general adult populations: A systematic review and metaanalysis**

Müller A, Mraz T, Wouters EFM, van Kuijk SMJ, Amaral AFS, Breyer-Kohansal R, Breyer MK, Hartl S, Janssen DYA.

Respiratory Medicine 2023, Aug;16 10.1016/j.rmed.2023.107379.

doi: 10.1016/j.rmed.2023.107379. Epub 2023 Aug 17. IF: 4.582

### **The Pleiotropic Role of Vitamin K in Multimorbidity of Chronic Obstructive Pulmonary Disease.**

Piscaer I, Janssen R, Franssen FME, Schurgers LJ, Wouters EFM.

J Clin Med. 2023 Feb 5;12(4):1261. doi: 10.3390/jcm12041261. IF: 5.41

## **2022**

### **Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan.**

Agustí A, Melén E, DeMeo DL, Breyer-Kohansal R, Faner R Lancet.

Respir Med. 2022 May;10(5):512-524. doi: 10.1016/S2213-2600(21)00555-5. Epub 2022 Apr 12.

IF: 30.7

### **Spirometry: The Indefinite Search for Gold.**

Wouters EFM, Breyer-Kohansal R.

Chest. 2022 Mar;161(3):593-594. doi: 10.1016/j.chest.2022.01.004. IF: 9.41

### **Take a breath – Is it time to re-think how we diagnose COPD?**

Wouters EFM, Breyer M.

Research Outreach 2022 Feb; Issue 128:78-79.

### **Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.**

Benson VS, Hartl S, Barnes N, Galwey N, Van Dyke MK, Kwon N.

Eur Respir J. 2022 Jan 13;59(1):2004590. doi: 10.1183/13993003.04590-2020. Print

2022 Jan. IF: 33.795

## **2021**

### **Nutritional Status and Body Composition in Patients Suffering From Chronic Respiratory Diseases and Its Correlation With Pulmonary Rehabilitation**

Wouters EFM.

Front Rehabil Sci. 2021 Dec 6;2:725534. doi: 10.3389/fresc.2021.725534. eCollection 2021. IF 5.058

### **Redox Dysregulation in Aging and COPD: Role of NOX Enzymes and Implications for Antioxidant Strategies.**

Schiffers C, Reynaert NL, Wouters EFM, van der Vliet A.

Antioxidants (Basel). 2021 Nov 11;10(11):1799. doi: 10.3390/antiox10111799. IF: 7.0

### **COPD Diagnosis: Time for Disruption**

Wouters EFM, Breyer MK, Breyer-Kohansal R, Hartl S.

JClin Med. 2021 Oct 11;10(20):4660. doi: 10.3390/jcm10204660. doi: 10.3390/jcm10204660.

IF: 2.659

### **Pre-Chronic Obstructive Pulmonary Disease: Toward the Limits of the Spirometric Funnel.** Wouters EFM.

Am J Respir Crit Care Med. 2021 Jul 1;204(1):112. doi: 10.1164/rccm.202103-0657LE.

IF: 21.405

### **Glutathione S-transferases and their implications in the lung diseases asthma and chronic obstructive pulmonary disease: Early life susceptibility?**

Van de Wetering C, Elko E, Berg M, Schiffers CHJ, Stylianidis V, van den Berge M, Nawijn MC, Wouters EFM, Janssen-Heininger YMW, Reynaert NL.

Redox Biol. 2021 Jul;43:101995. doi: 10.1016/j.redox.2021.101995. Epub 2021 May 2.

IF: 11.799

### **The prevalence and related factors of fatigue in patients with COPD: a systematic review.** Ebadi Z, Goërtz

YMJ, Van Herck M, Janssen DJA, Spruit MA, Burtin C, Thong MSY, Muris J, Otker J,

Looijmans M, Vlasblom C, Bastiaansen J, Prins J, Wouters EFM, Vercoulen JH, Peters JB.

Eur Respir Rev. 2021 Apr 13;30(160):200298. doi: 10.1183/16000617.0298-2020.

Print 2021 Jun 30. IF: 16.671

### **Transitioning from infancy to adulthood: a black box full of opportunities.**

Agusti A, Breyer-Kohansal R, Faner R.

Eur Respir J. 2021 Mar 4;57(3):2003997. doi: 10.1183/13993003.03997-2020. Print 2021 Mar. IF: 12.339

## **2020**

### **Skin autofluorescence: early sign of lung function deterioration?**

Wouters EFM, Reynaert NL.

ERJ Open Res. 2020 Jul 20;6(2):00368-2020. doi: 10.1183/23120541.00368-2020. eCollection 2020 Apr.

IF: 4.2

## **2019**

### **Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration.**

Agusti A, Faner R, Donaldson G, Heuvelin E, Breyer-Kohansal R, Melén E, Maitland-van der Zee AH, Vestbo J, Allinson JP, Vanfleteren LEGW, van den Berge M, Adcock IM, Lahousse L, Brusselle G, Wedzicha JA;

on behalf of the CADSET Clinical Research Collaboration; Current members of the CADSET Clinical Research Collaboration. Eur Respir J. 2019 Mar 18;53(3):1900217. doi: 10.1183/13993003.00217-2019. Print 2019 Mar. IF: 12.339

## **Collaborative publications**

## **2024**

### **Enhancing Heart Failure Care: Deep Learning-Based Activity Classification in Left Ventricular Assist Device Patients.**

Berger L, Habermusch M, Gross C, Moscato F.

ASAIO J. 2024 Sep 5. doi: 10.1097/MAT.0000000000002299. Epub ahead of print. IF.: 3.1

**ERS International Congress 2023: highlights from the Basic and Translational Sciences Assembly.**

Reddy KD, Bizymi N, Schweikert A, Ananth S, Lim CX, Lodge KM, Joannes A, Ubags N, van der Does AM, Cloonan SM, Mailleux A, Mansouri N, Reynaert NL, Heijink IH, Cuevas-Ocaña S.  
ERJ Open Res. 2024 Apr 29;10(2):00875-2023. doi: 10.1183/23120541.00875-2023. IF: 24.3

**Association between lung function and dyspnoea and its variation in the multinational Burden of Obstructive Lung Disease (BOLD) study.**

Müller A, Wouters EF, Koul P, Welte T, Harrabi I, Rashid A, Loh LC, Al Ghobain M, Elsony A, Ahmed R, Potts J, Mortimer K, Rodrigues F, Paraguas SN, Juvekar S, Agarwal D, Obaseki D, Gislason T, Seemungal T, Nafees AA, Jenkins C, Dias HB, Franssen FME, Studnicka M, Janson C, Cherkaski HH, El Biaze M, Mahesh PA, Cardoso J, Burney P, Hartl S, Janssen DJA, Amaral AFS.  
Pulmonology. 2024 Apr 13:S2531-0437(24)00044-8. doi: 10.1016/j.pulmoe.2024.03.005.  
Epub ahead of print. IF: 11.7

**Alterations in stride-to-stride fluctuations in patients with chronic obstructive pulmonary disease during a self-paced treadmill 6-minute walk test.**

Liu WY, Spruit MA, Delbressine JM, Willems PJ, Yentes JM, Bruijn SM, Franssen FME, Wouters EFM, Mei PLoS One. 2024 Mar 15;19(3):e0300592. doi: 10.1371/journal.pone.0300592. jcr K. IF: 3.7

**Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study**

Abozid H, Patel J, Burney P, Hartl S, Breyer-Kohansal R, Mortimer K, Nafees AA, Al Ghobain M, Welte T, Harrabi I, Denguezli M, Li Cher Loh, Rashid A, Gislason T, Cristina B, Joao J, Rodrigues F, Seemungal T, Obaseki D, Juvekar S, Nonna Paraguas S, Wan C Tan, Franssen FME, Mejza F, Mannino D, Janson C, Cherkaski HH, Anand MP, Hafizi H, Buist S, Koul P A, El Sony A, Breyer MK, Burghuber OC, Wouters EFM, Amaral AFS; BOLD Collaborative Research Group  
EClinicalMedicine. 2024 Jan 21;68:102423. eCollection 2024 Feb.  
doi: 10.1016/j.eclinm.2024.102423. eCollection 2024 Feb. IF: 15.1

**2023**

**Characteristics of Current Smokers versus Former Smokers with COPD and Their Associations with Smoking Cessation Within 4.5 Years: Results from COSYCONET**

Alter P, Stoleriu C, Kahnert K, Henke MO, Bals R, Trudzinski FC, Watz H, Speicher T, Söhler S, Welte T, F Rabe KF, Wouters EFM, Vogelmeier CF, Jörres RA  
Int J Chron Obstruct Pulmon Dis. 2023;18:2911-2923. doi: 10.2147/COPD.S436669. eCollection 2023. IF: 2.8

**The association of spirometric small airways obstruction with respiratory symptoms, cardiometabolic diseases, and quality of life: results from the Burden of Obstructive Lung Disease (BOLD) study.**

Knox-Brown B, Patel J, Potts J, Ahmed R, Aquart-Stewart A, Barbara C, Buist AS, Cherkaski HH, Denguezli M, Elbiaze M, Erhabor GE, Franssen FME, Al Ghobain M, Gislason T, Janson C, Kocabaş A, Mannino D, Marks G, Mortimer K, Nafees AA, Obaseki D, Paraguas SNM, Li Cher Loh, Rashid A, Salvi S, Seemungal T, Studnicka M, Wan C Tan, Wouters EFM, Abozid H, Mueller A, Burney P, Amaral AFS  
Respir Res. 2023 May 23;24(1):137. doi: 10.1186/s12931-023-02450-1. IF: 7.16

**CT airway remodelling and chronic cough**

Abozid H, Kirby M, Nasir N, Hartl S, Breyer-Kohansal R, Breyer MK, Burghuber OC, Bourbeau J, Wouters EFM, Wan Tan BMJ.  
BMJ Open Respir Res. 2023 May;10(1):e001462. doi: 10.1136/bmjresp-2022-001462. IF: 7.162



**Combined analysis of five non-interventional studies of the effectiveness, tolerability, and safety of the extrafine fixed dose beclomethasone/formoterol combination in the treatment of asthma in Austria.**

Renner A, Marth K, Breyer-Kohansal R, Pohl W.

Respir Med. 2023 Feb;207:107097. doi: 10.1016/j.rmed.2022.107097.

Epub 2022 Dec 27. IF: 4.582

**Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort.**

Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, Söhler S, Welte T, Rabe KF, Wouters EFM, Vogelmeier CF, Jörres RA.

Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231208584. doi: 10.1177/17534666231208584. IF: 4.3

**2021**

**Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease-A 10-Year Cohort Study.**

Urban MH, Stojkovic S, Demyanets S, Hengstenberg C, Valipour A, Wojta J, Burghuber OC.

J Clin Med. 2021 Dec 23;11(1):56. Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease-A 10-Year Cohort Study. doi: 10.3390/jcm11010056. IF: 5.410

**Downregulation of DUOX1 function contributes to aging-related impairment of innate airway injury responses and accelerated senile emphysema.**

Schiffers C, Lundblad LKA, Hristova M, Habibovic A, Dustin CM, Daphtary N, Aliyeva M, Seward DJ, Janssen-Heininger YMW, Wouters EFM, Reynaert NL, van der Vliet A.

Am J Physiol Lung Cell Mol Physiol. 2021 Jul 1;321(1):L144-L158.

doi: 10.1152/ajplung.00021.2021. Epub 2021 May 5. IF: 4.659

**Effects of Dynamic Hyperinflation on Left Ventricular Diastolic Function in Healthy Subjects - A Randomized Controlled Crossover Trial.**

Urban MH, Mayr AK, Schmidt I, Grasmuk-Siegl E, Burghuber OC, Funk GC.

Front Med (Lausanne). 2021 May 4;8:659108. doi: 10.3389/fmed.2021.659108.

eCollection 2021. IF: 5.058

**Induction of dynamic hyperinflation by expiratory resistance breathing in healthy subjects - an efficacy and safety study.**

Urban MH, Mayr AK, Schmidt I, Margulies E, Grasmuk-Siegl E, Burghuber OC, Funk GC.

Exp Physiol. 2021 Feb;106(2):532-543. Epub 2020 Nov 23. doi: 10.1113/EP088439. IF: 2.858

**Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.**

Urban MH, Kreibich N, Gleiss A, Funk GC, Hartl S, Burghuber OC.

Respirology. 2021 Feb;26(2):153-160. doi: 10.1111/resp.13914. Epub 2020 Jul 28. IF: 4.880

**Downregulation of epithelial DUOX1 in chronic obstructive pulmonary disease.**

Schiffers C, van de Wetering C, Bauer RA, Habibovic A, Hristova M, Dustin CM, Lambrichts S, Vacek PM, Wouters EF, Reynaert NL, van der Vliet A.

JCI Insight. 2021 Jan 25;6(2):e142189. doi: 10.1172/jci.insight.142189. IF: 6.205



2020

**Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria - Results from the CLARA Project.**

Horner A, Burghuber OC, Hartl S, Studnicka M, Merkle M, Olschewski H, Kaiser B, Wallner EM, Lamprecht B.

Int J Chron Obstruct Pulmon Dis. 2020 Jul 12;15:1655-1663. doi: 10.2147/COPD.S252033. eCollection 2020. IF: 3.157

**Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report.**

Schnaubelt S, Breyer MK, Siller-Matula J, Domanovits H.

Eur Heart J Case Rep. 2020 Jun 24;4(F11):1-6. doi: 10.1093/ehjcr/ytaa166. eCollection 2020 Oct. IF: 24.889

2019

**The European COPD audit: Adherence to guidelines, readmission risk and hospital care for acute exacerbations in Austria.**

Breyer-Kohansal R, Hartl S, Breyer MK, Schrott A, Studnicka M, Neunhäuserer D, Fül.p G, Burghuber OC.

Wien Klin Wochenschr 2019 Mar;131(5-6):97-103. doi: 10.1007/s00508-019-1441-5. Epub 2019 Jan 28. IF: 1.704

*Publications Programme Line 2 Clinical Research*

2024

**The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.**

Gray JE, Schenker M, Nahit Şendur MA, Leonova V, Kowalski D, Kato T, Orlova R, Chih-Hsin Yang J, Langleben A, Pilz A, Ungureanu A, Mak MP, Flavia De Angelis, Aggarwal H, Zimmer Z, Zhao B, Shamoun M, Kim TM. J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435-3. doi: 10.1016/j.jtho.2024.10.026. Epub ahead of print. IF: 21.0

**Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.**

Andric Z, Califano R, Veatch A, Gerstner G, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV. Lung Cancer. 2024 Oct;196:107924. doi: 10.1016/j.lungcan.2024.107924. Epub 2024 Aug 10. IF.: 4.5

**A Multivariant Surrogate Virus Neutralization Test Demonstrates Distinct SARS-CoV-2-Specific Antibody Responses in People Living with HIV after a Fourth Monovalent mRNA Vaccination or an Omicron Breakthrough Infection.**

Springer DN, Daller S, Knappik M, Prüger K, Hartl S, Breyer-Kohansal R, Puchhammer-Stöckl E, Aberle JH, Weseslindtner L, Breyer MK.

Diagnostics (Basel). 2024 Apr 16;14(8):822. doi: 10.3390/diagnostics14080822. IF: 3.6

## **Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial**

Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13. IF: 82.9

## **2023**

### **A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.**

Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang- We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-Long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de Marinis  
Future Oncol. 2023 Jan;19(1):61-75. doi: 10.2217/fon-2022-0919. Epub 2023 Jan 19. IF: 3.3

## **2021**

### **Lung Cancer in Austria.**

Pirker R, Prosch H, Popper H, Klepetko W, Dieckmann K, Burghuber OC, Klikovits T, Hoda MA, Zöchbauer-Müller S, Filipits M.  
J Thorac Oncol. 2021 May;16(5):725-733. doi: 10.1016/j.jtho.2020.10.158. IF: 20.121

### **Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients.**

Hackner K, Buder A, Hochmair MJ, Strieder M, Grech C, Fabikan H, Burghuber OC, Errhalt P, Filipits M.  
Clin Med Insights Oncol. 2021 Feb 17;15: 1179554921993072. doi: 10.1177/1179554921993072. eCollection 2021. IF: 4.925

## **2020**

### **Results of the Austrian National Lung Cancer Audit.**

Burghuber, OC, Kirchbacher K, Mohn-Staudner A, Hochmair M, Breyer M.-K, Studnicka M, Mueller M. R, Feurstein P, Schrott A, Lamprecht B, Eckmayr J, Renner F, Bolitschek J, Pohl W, Schenk P, Errhalt P, Cerkl P, Baumgartner B, Kneussl M, Hartl S.  
Clin Med Insights Oncol. 2020 Sep 10; 14:1179554920950548, doi: 10.1177/1179554920950548. eCollection 2020. IF: 3.355

## **2019**

### **EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.**

Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, Burghuber OC, Pirker R, Filipits M.  
Target Oncol 2019 Apr;14(2):197-203. doi: 10.1007/s11523-019-00623-x. IF: 4.036.

**Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.**

Hochmair MJ, Buder A, Schwab S, et al.

Target Oncol 2019 Feb;14(1):75–83. doi: 10.1007/s11523-018-0612-z. IF: 4.036

**Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).**

Halmos B, Tan E-H, Soo RA, Burghuber OC; et al.

Lung Cancer 2019 Jan;127:103–11. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2. IF: 4.702